Participation in a specialty pharmacy improved control of secondary hyperparathyroidism in hemodialysis patients, researchers reported at ASN’s Renal Week 2009.
Cinacalcet therapy is safe and effective for treating persistent hyperparathyroidism after renal transplantation, British researchers reported at ASN’s Renal Week 2009. The medication is not associated with allograft dysfunction or significant adverse effects.
Obesity in CKD patients is associated with increased parathyroid hormone levels independent of estimated glomerular filtration rate, according to a study presented at ASN’s Renal Week 2009.
Among patients with stages III-IV CKD, African-American race is associated with a decreased parathyroid hormone response to oral calcitriol, according to a study presented at ASN’s Renal Week 2009.
Loop diuretics increase the risk of secondary hyperparathyroidism in CKD patients, but concurrent use of thiazide diuretics attenuate that risk, data suggest according to a study that was presented at ASN’s Renal Week 2009.
Cinacalcet showed long-term efficacy in reducing serum parathyroid hormone and calcium levels in renal transplant patients with refractory tertiary hyperparathyroidism, according to a study presented at ASN’s Renal Week 2009.
Higher intact parathyroid hormone levels are not associated with all-cause mortality and cardiovascular events in CKD patients not yet on dialysis, researchers have concluded in a study that was presented at Renal Week 2009.
Oral alfacalcidol is effective in controlling secondary hyperparathyroidism with an adjusted dose 1.5 times that of oral calcitriol, a study showed.
Cinacalcet treatment following renal transplantation is associated with improved bone remodeling, a study found.